Focused On-demand Library for Conserved oligomeric Golgi complex subunit 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UP83

UPID:

COG5_HUMAN

Alternative names:

13S Golgi transport complex 90 kDa subunit; Component of oligomeric Golgi complex 5; Golgi transport complex 1

Alternative UPACC:

Q9UP83; A4D0R6; A4D0R7; O14555; O95008; Q6NUL5

Background:

The Conserved oligomeric Golgi complex subunit 5, known by its alternative names such as 13S Golgi transport complex 90 kDa subunit, Component of oligomeric Golgi complex 5, and Golgi transport complex 1, plays a pivotal role in maintaining normal Golgi function. This protein is integral to the process of glycoprotein biosynthesis, ensuring the proper assembly and function of glycoproteins within the cell.

Therapeutic significance:

The protein's malfunction is directly linked to Congenital disorder of glycosylation 2I, a multisystem disorder characterized by a broad spectrum of clinical features including neurological impairments, psychomotor retardation, and immunodeficiency. Understanding the role of Conserved oligomeric Golgi complex subunit 5 could open doors to potential therapeutic strategies for this disorder, highlighting its critical role in embryonic development and cell function maintenance.